SYK

Business Context and Reporting Period

Company: Stryker Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2004
Business Overview: Stryker is a global leader in orthopaedic and medical device markets, operating through two primary segments: Orthopaedic Implants and MedSurg Equipment. The company also provides Physical Therapy Services. All share and per-share data reflect a two-for-one stock split effective May 14, 2004.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16% in the third quarter and 18% for the nine-month period compared to 2003. Growth was driven by increased unit volume, favorable product mix, and higher selling prices. International sales grew 16% (Q3) and 18% (9M), with foreign currency providing a favorable impact of $24.9 million in Q3 and $94.8 million for the nine months.
• Profitability Impact: Reported net earnings decreased 87% in Q3 and 5% for the nine months compared to 2003. This decline is primarily due to a one-time non-cash charge of $120.8 million for purchased in-process research and development (IPR&D) related to the acquisition of SpineCore, Inc.
• Adjusted Performance: Excluding the $120.8 million IPR&D charge, adjusted net earnings increased 25% in Q3 and 33% for the nine months. Adjusted diluted EPS was $0.33 for Q3 and $1.03 for the nine months.
• Cost Structure: Cost of sales as a percentage of sales improved to 35.5% in Q3 (from 37.1% in 2003) due to manufacturing efficiencies and lower raw material costs. SG&A expenses increased 17% in Q3, largely due to higher sales commissions and insurance costs.
• Liquidity: Working capital increased to $855.1 million. The company fully repaid amounts outstanding under its accounts receivable securitization facility ($150.0 million) during the period.

Guidance, Outlook, and Risks

• 2004 Outlook: Management expects diluted net earnings per share to approximate $1.14 for the full year 2004, after the impact of the SpineCore charge. Net sales growth is projected in the range of 17% to 18%, driven by Orthopaedic Implants, MedSurg Equipment, and Physical Therapy Services.
• Currency Impact: If exchange rates hold at current levels, the company anticipates a favorable impact of approximately $105 million on full-year 2004 net sales.
• Capital Allocation: The company has paid down all outstanding borrowings under credit facilities and expects to generate cash earnings in excess of working capital needs. Future investments will focus on acquisitions, new product launches, and facility expansions.
• Risks and Contingencies:
  • SpineCore Acquisition: Potential milestone and royalty payments of up to $240.0 million are contingent on commercialization, not expected before 2008. Risks include FDA approval delays and clinical study outcomes.
  • Market Risks: Exposure to regulatory actions, reimbursement level changes, product liability claims, and foreign exchange fluctuations.

Investor Verification Checklist

• SpineCore Integration: Verify the timeline for FDA approval and commercialization of SpineCore's artificial disc technologies to assess the likelihood of future milestone payments.
• Inventory Levels: Days sales in inventory increased to 136 days (from 120 days); confirm if this buildup aligns with anticipated 2004/2005 product launches or indicates demand softness.
• Accounts Receivable Aging: Days sales outstanding increased to 61 days; review the specific aging of receivables in the U.S. and Europe mentioned in the filing.
• Non-GAAP Reconciliation: Review the reconciliation of adjusted earnings to ensure the exclusion of the $120.8 million IPR&D charge accurately reflects core operating performance.
• Debt Capacity: Confirm the availability of the $804.3 million in remaining borrowing capacity and the $200.0 million securitization facility for future strategic moves.